Articles & Resources

Cell Therapy

Below is a collection of articles, resources and stories from the Invetech team and industry experts, sharing their knowledge, experiences and advice on product development and market trends.

Cell Therapy

Clear filter

Key Considerations for Automating Cell Therapy Manufacturing Processes

Invetech’s Jon Ellis and TreeFrog Therapeutics’ Maxime Feyeux discuss cell therapy process automation, development time and costs and automating ancillary processes.

Rethink Cell Therapy QC with Release by Exception

The cell and gene therapy industry could move away from lengthy and costly QC reviews - while still upholding high quality standards - by employing release by exception methods.

Reducing the Manufacturing Costs of Allogeneic Cell Therapies

For allogeneic cell therapies to reach their therapeutic potential, it comes down to achieving scalable and robust manufacturing processes.

Integrating Ancillary Systems – A Bridge to Closed Cell Therapy Manufacturing Processes

Removing bottlenecks around media formulation, viral vector preparation and unique cell therapy reagents.

Driving Down Costs of Autologous Cell Therapy Manufacturing

Panelists from Acepodia, Celyad and SOTIO discuss how cell therapies are impacted by the high cost of manufacturing and share their insights on ways to drive down costs.

Commercializing Disruptive Technologies in Advanced Therapies

From the back of the napkin to the bedside: Panelists from CUTISS, Humacyte and TreeFrog Therapeutics share their inspirational journeys commercializing disruptive technologies

Got Approval… Now What? Meeting Cell Therapy Market Demand

Panelists from bluebird bio, DiscGenics and Proteus, LLC share their vision for commercial manufacturing of cell therapies.

Navigating the Cost and Time of Cell Therapy Manufacturing Process Automation

In this article, we discuss available devices and technology developments for cell therapy products in preclinical, clinical and early commercialization phases.

Avoiding the Potholes Along the Pathway to Commercial Cell Therapies

Panelists from Cell Therapies, Duke University and Fate Therapeutics discuss how they envision the road ahead for some of the biggest challenges in cell therapy manufacturing.

What’s Next for Commercial Cell Therapy Manufacturing?

Now it's getting serious. Panelists from bluebird bio, Juno Therapeutics and Hitachi Chemical Advanced Therapeutics Solutions (HCATS) discuss their vision for the coming era of industrialized cell therapy production.

Ensuring Bioprocess Flexibility for Cell Therapy Production

Choosing cell therapy production equipment that is suitable for the current stage of development and will also enable smooth transfer to commercial manufacture.

The Human Side of Stem Cell Therapies

Reporting from ISSCR 2018, the world's largest stem cell-focused meeting, Invetech scientist Alan Ching is reminded of the importance of this industry.